파킨슨병 시장 : 2033년까지의 역학적 예측

Parkinson's disease (PD) is an incurable neurodegenerative disease clinically categorized as a movement disorder with prominent motor symptoms, including tremors, rigidity, and bradykinesia (Hoehn and Yahr, 1967; Poewe et al., 2017). The clinical presentation of PD is characterized by postural instability, resting tremors, and gait problems that result from the progressive loss of A9 dopaminergic neurons in the substantia nigra pars compacta (Delic et al., 2020). PD is associated with motor symptoms involving bradykinesia, resting tremor, rigidity, and postural disturbances, as well as non-motor symptoms, including hyposmia, rapid eye movements, sleep behavior disorder, and depression (World Health Organization, 2023). PD is the second most common chronic progressive neurodegenerative disorder in the elderly, following Alzheimer's disease, and affects 1-2% of individuals ages 65 years and older worldwide (Mhyre et al., 2012; Kowal et al., 2013). At present, there are no blood or laboratory tests to diagnose non-genetic cases of PD. Diagnosis is primarily based on a patient's medical history and neurological examination. An additional hallmark that supports a PD diagnosis is a patient's improvement after starting medication. While current treatments provide symptomatic relief, there is still no therapy available to halt or slow the progression of the disease. Although a cure for PD remains elusive, existing treatments-such as medications, surgical interventions, and therapies like physiotherapy and occupational therapy-help manage key symptoms and preserve quality of life for as long as possible (National Health Service, 2022; National Institute on Aging, 2022).

In 2023, there were 2,636,930 diagnosed prevalent cases of PD among men and women ages 18 years and older across the 7MM. The US had the highest number of cases at 974,348, while Spain had the fewest, with 131,264 cases. Across the 7MM, the diagnosed prevalent cases of PD are projected to rise to 3,147,624 cases by 2033 at an annual growth rate (AGR) of 1.94% over the forecast period. This increase in the diagnosed prevalent cases of PD across the 7MM is primarily attributed to changes in the underlying population demographics, as GlobalData epidemiologists assumed a constant prevalence rate during the forecast period.

Scope

• This report provides an overview of the risk factors, comorbidities, and global and historical trends for PD in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan).
• The report features a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by sex and age (beginning at age 18 years and ending at ages 85 years and older).
• The diagnosed prevalent cases are further categorized by Hoehn and Yahr (HY) clinical staging (stages I, II, III, IV, and V) and grouped into early (equivalent to HY clinical stages I-II), moderate-advanced (equivalent to HY clinical stages III-V), and advanced (equivalent to HY clinical stages IV-V). Additionally, the report covers diagnosed prevalent cases based on the inheritance type, including sporadic (idiopathic) and familial forms of PD.
• It also includes segments on motor complications, such as motor fluctuations and levodopa-induced dyskinesia, as well as neuropsychiatric complications, classified into psychosis, dementia, and hallucinations.
• To forecast the diagnosed prevalent cases of PD in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data. In addition, the forecast is supported by robust, country-specific data obtained from various authentic sources, such as research articles published in peer-reviewed journals.

Reasons to Buy

• The Parkinson's disease (PD) epidemiology series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global PD market.
• Quantify patient populations in the global PD market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for PD therapeutics in each of the markets covered.

Table of Contents

Table of Contents

• About GlobalData

1 Parkinson's Disease: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Forecast assumptions and methods: diagnosed prevalent cases of PD
  • 2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of PD by HY clinical staging
  • 2.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PD by inheritance type
  • 2.4.6 Forecast assumptions and methods: diagnosed prevalent cases of PD by motor complications
  • 2.4.7 Forecast assumptions and methods: diagnosed prevalent cases of PD by neuropsychiatric complications
• 2.5 Epidemiological forecast for PD (2023-33)
  • 2.5.1 Diagnosed prevalent cases of PD
  • 2.5.2 Age-specific diagnosed prevalent cases of PD
  • 2.5.3 Sex-specific diagnosed prevalent cases of PD
  • 2.5.4 Diagnosed prevalent cases of PD by HY clinical staging
  • 2.5.5 Diagnosed prevalent cases of PD by type
  • 2.5.6 Diagnosed prevalent cases of PD by inheritance type
  • 2.5.7 Diagnosed prevalent cases of PD by motor complications
  • 2.5.8 Diagnosed prevalent cases of PD by neuropsychiatric complications
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Intelligence and Epidemiology
  • 3.2.4 Global Head of Pharma Research, Analysis and Competitive Intelligence
• Contact Us